IBD - a potential adverse effect of DDP4 inhibitors in T2DM

Nat Rev Endocrinol. 2018 Jun;14(6):323. doi: 10.1038/s41574-018-0007-3.
No abstract available

Publication types

  • Comment

MeSH terms

  • Cohort Studies
  • Diabetes Mellitus, Type 2*
  • Dipeptidyl-Peptidase IV Inhibitors*
  • Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
  • Humans
  • Incidence
  • Inflammatory Bowel Diseases*

Substances

  • Dipeptidyl-Peptidase IV Inhibitors
  • Dipeptidyl-Peptidases and Tripeptidyl-Peptidases